The First Affiliated Hospital Of Xiamen University

This study tests an oral medication called tofacitinib in 8 people with moderate-to-severe thyroid eye disease who did not improve with or could not take steroids. The drug works by blocking inflammation pathways. Researchers will check if it reduces eye bulging and other symptom…

This phase II trial tests whether giving trilaciclib before sacituzumab tirumotecan can protect bone marrow in patients with advanced EGFR-mutated non-small cell lung cancer that has stopped responding to standard treatments. About 49 participants will receive the drug combo and …

This early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…

This phase 2 trial is testing a combination of three drugs—venetoclax, chidamide, and azacitidine—in 30 adults with acute myeloid leukemia that has relapsed or not responded to prior treatment. The goal is to see if this combo can safely improve remission rates and survival. Part…

This study tests a new radioactive tracer called 68Ga-GPC3 that targets a protein found on liver cancer cells. About 40 adults with suspected or confirmed hepatocellular carcinoma will receive both this new tracer and a standard tracer (18F-FDG) for PET/CT scans. Researchers will…

This study tests a new type of PET/CT scan that looks for a protein called DLL3 on small cell lung cancer cells. The goal is to see if this scan can find tumors more clearly than standard imaging methods like CT or regular PET scans. About 20 adults with suspected or confirmed sm…

This study tests a new radioactive tracer called 68Ga-NK224 that lights up PD-L1, a protein on cancer cells, during a PET/CT scan. Researchers want to see if the scan can accurately measure PD-L1 levels compared to standard tissue biopsy. One hundred adults with various cancers w…

This study is testing a new type of PET scan that targets a protein called DLL3, found on some neuroendocrine cancer cells. The goal is to see if this scan can find tumors more accurately than current imaging methods. About 60 adults with suspected or confirmed neuroendocrine can…

This study aims to see if a new type of PET scan (called 68Ga-XACP3) can find prostate cancer tumors as well as or better than the current standard scan (68Ga-PSMA). About 60 adults with newly diagnosed, suspected recurrent, or treated prostate cancer will receive both scans. The…

This study is testing whether a special PET scan using a tracer called 68Ga-MY6349 can predict how well a targeted therapy (Trop2-ADC) works in people with advanced non-small cell lung cancer (NSCLC). Fifty adult patients will receive the scan before and during treatment. The goa…

This study tests whether transcutaneous electrical acupoint stimulation (TEAS) can reduce gastrointestinal dysfunction after urological laparoscopic surgery. 112 adults undergoing procedures like laparoscopic nephrectomy will receive either real or sham TEAS before and after surg…

This early study tests eye drops made from stem cell particles in 20 adults with dry eye disease. Participants use the drops four times daily for four weeks. Researchers track safety and symptom changes like eye staining and tear film stability.